Organizational and applied aspects of follow-up monitoring of patients with prediabetes by a primary care physician. Expert council resolution

The steady increase in the prevalence of carbohydrate metabolism disorders worldwide, with the vast majority of type 2 diabetes (T2D), specifies the need to improve disease prevention measures. A special niche in the preventive continuum is occupied by early carbohydrate metabolism disorders, the treatment of which makes a significant contribution to T2D prevention. The absence of a characteristic clinical performance, inadequate apprehensive attitude of healthcare professionals contributes to unnoticed development of carbohydrate metabolism disorders, while progressive disorders lead to micro-, macrovascular complications and the manifestation of T2D. On September 16, 2024, under the chairmanship of Academician of the Russian Academy of Sciences O. M. Drapkina and under the aegis of the Russian Society for the Prevention of Noncommunicable Diseases, the Expert Council was held  on  Organizational  and  Applied  Aspects  of  Follow-up  Monitoring  of  Patients  with  Prediabetes  by a General Practitioner. The meeting was attended by the main external experts in internal medicine of regional health protection executive authorities, leading experts of the National Medical Research Center for Therapy and Preventive Medicine and regional branches of the Russian Society for the Prevention of Noncommunicable Diseases, who presented current related problems and proposals for their solution. The Expert Council resolution is presented in this article.

1. Drapkina OM, Drozdova LYu, Shepel RN, et al. Analysis of prediabetes prevalence and real-world practice in prescribing drug therapy to prediabetic patients. The Russian Journal of Preventive Medicine. 2022;25(12):96-105. (In Russ.) doi:10.17116/profmed20222512196.

2. Petunina NA, Martirosian NS, Khachaturov MV, et al. Diagnosis and treatment of prediabetes as prevention of type 2 diabetes: A review. Consilium Medicum. 2023;25(4):229-35. (In Russ.) doi:10.26442/20751753.2023.4.202312.

3. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.

4. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes Mellitus. 2023;26(2):104-23. (In Russ.) doi:10.14341/DM13035.

5. Haw JS, Galaviz KI, Straus AN, et al. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2017;177(12):1808-17. doi:10.1001/jamainternmed.2017.6040.

6. Kerrison G, Gillis RB, Jiwani SI, et al. The Effectiveness of Lifestyle Adaptation for the Prevention of Prediabetes in Adults: A Systematic Review. J Diabetes Res. 2017;2017:8493145. doi:10.1155/2017/8493145.

7. Zhou X, Siegel KR, Ng BP, et al. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review. Diabetes Care. 2020;43(7):1593-616. doi:10.2337/dci20-0018.

8. Bosetti R, Tabatabai L, Naufal G, et al. Comprehensive cost-effectiveness of diabetes management for the underserved in the United States: A systematic review. PLoS One. 2021;16(11):e0260139. doi:10.1371/journal.pone.0260139.

9. Schlesinger S, Neuenschwander M, Barbaresko J, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;65:275-85. doi:10.1007/s00125-021-05592-3.

10. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-86. doi:10.1016/S0140-6736(09)61457-4.

11. Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42:601-8. doi:10.2337/dc18-1970.

12. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-31. doi:10.2337/diacare.26.3.725.

13. Mustafina SV, Rymar OD, Sazonova OV, et al. Validation of the Finnish diabetes risk score (FINDRISC) for the Caucasian population of Siberia. Diabetes Mellitus. 2016;19(2):113-8. (In Russ.) doi:10.14341/DM200418-10.